The Prevalence of Darunavir-Associated Mutations in HIV-1-Infected Children in the Uk

Mills A.M. , Nelson M. , Jayaweera D. Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23: 1679–1688.

Madruga J.V. , Berger D. , McMurchie M. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir–ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITIAN: a randomised controlled Phase III trial. Lancet 2007; 370: 49–58.

Clotet B. , Bellos N. , Molina J.M. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169–1178.

Blanche S. , Bologna R. , Cahn P. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS 2009; 23: 2005–2013.

PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10: 591–613.

Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection; pp. 1–219. (Updated 16 August 2010. Accessed 6 December 2010.) Available from http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.

PREZISTA^® (darunavir). Summary of product characteristics. (Updated August 2010. Accessed 31 October 2010.) Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000707/WC500041756.pdf.

Violari A. , Bologna R. , Kimutai R. ARIEL: 24-week safety and efficacy of DRV/r in treatment-experienced 3 to <6 year old patients. 18th Conference on Retroviruses and Opportunistic Infection. 27 February–11 March 2011, Boston, MA, USA. Poster 713.

de Meyer S. , Vangeneugden T. , Van Baelen B. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008; 24: 379–388.

de Meyer S. , Dierynck I. , Lathouwers E. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment experienced patients in POWER 1, 2, 3 and DUET-1 and 2. Antivir Ther 2009; 13 Suppl 3: A33.

De La Rosa G. , Pattery T. , Picchio G. , Lathouwers E. , Villacian J. , Van der Borght K. Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009. 10th International Congress on Drug Therapy in HIV Infection. 7–11 November 2010, Glasgow, UK. Poster P132.

de Meyer S. , Descamps D. , Van Baelen B. Confirmation of the negative impact of protease mutations I47V, I54M, T74P AND I84V and the positive impact of protease mutation V82A on virological response to darunavir/ ritonavir. Antivir Ther 2009; 14 Suppl 1: A147.

Judd A. , Doerholt K. , Tookey P.A. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996–2006: planning for teenage and adult care. Clin Infect Dis 2007; 45: 918–924.

Johnson V.A. , Brun-Vézinet F. , Clotet B. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2010; 18: 156–163.

Pillay D. , Green H. , Matthias R. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 2005; 192: 967–973.